FUTURE-DEVELOPMENTS IN IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS - THE OPTIMAL DEVICE

被引:7
作者
CALLANS, DJ
JOSEPHSON, ME
机构
[1] HOSP UNIV PENN,CLIN ELECTROPHYSIOL LABS,PHILADELPHIA,PA 19104
[2] HOSP UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104
[3] HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215
关键词
D O I
10.1016/0033-0620(93)90016-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite recent therapeutic advances, SCD remains the leading cause of mortality in industrialized nations. The most frequent cause of SCD is ventricular tachyarrhythmias in the setting of advanced structural heart disease due to chronic coronary heart disease or idiopathic dilated cardiomyopathy. Although high-risk groups can be prospectively identified, attempts at primary prevention have been largely unsuccessful. Effective treatment strategies for SCD survivors include antiarrhythmic drug therapy guided by programmed stimulation, endocadial resection, and ICDs. Device therapy has proven extremely effective in preventing recurrent sudden death from ventricular tachyarrhythmias. Widespread application of ICD therapy, perhaps even to include members of high-risk populations that have not experienced cardiac arrest, will depend on many factors including the demonstration that device therapy improves total mortality, not just arrhythmia-related mortality, reduction in cost, and improvements in the devices themselves. Some of the important characteristics of the optimal ICD of the future are nonthoracotomy lead placement; subpectoral generator placement; multiprogrammable, tiered therapy; improved diagnostic specificity, whether based on electrogram or hemodynamic-sensing algorithms; improved integration of brady- and tachy-sensing systems; and enhanced electrogram storage capability with trans-telephonic retrieval of electrogram recordings. The creation of this ideal ICD will obviously require continued technological advances; however, given the tremendous improvements realized over the first three generations of ICD systems, optimism for the future seems warranted. © 1993.
引用
收藏
页码:227 / 244
页数:18
相关论文
共 121 条
[11]   CLINICAL INTERACTIONS BETWEEN PACEMAKERS AND AUTOMATIC IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS [J].
CALKINS, H ;
BRINKER, J ;
VELTRI, EP ;
GUARNIERI, T ;
LEVINE, JH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 16 (03) :666-673
[12]   USE OF BIPOLAR RECORDINGS FROM PATCH-PATCH AND RATE SENSING LEADS TO DISTINGUISH VENTRICULAR-TACHYCARDIA FROM SUPRAVENTRICULAR RHYTHMS IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS [J].
CALLANS, DJ ;
HOOK, BG ;
MARCHLINSKI, FE .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (11) :1917-1922
[13]   PACED BEATS FOLLOWING SINGLE NONSENSED COMPLEXES IN A CODEPENDENT CARDIOVERTER DEFIBRILLATOR AND BRADYCARDIA PACING SYSTEM - POTENTIAL FOR VENTRICULAR-TACHYCARDIA INDUCTION [J].
CALLANS, DJ ;
HOOK, BG ;
MARCHLINSKI, FE .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (08) :1281-1287
[14]  
CALLANS DJ, IN PRESS J AM COLL C
[15]   THE AUTOMATIC IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR - EVALUATING SUSPECTED INAPPROPRIATE SHOCKS [J].
CHAPMAN, PD ;
TROUP, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (05) :1075-1078
[16]   A THEORETICALLY AND PRACTICALLY MORE EFFECTIVE METHOD FOR INTERRUPTION OF VENTRICULAR-TACHYCARDIA - SELF-ADAPTING AUTODECREMENTAL OVERDRIVE PACING [J].
CHAROS, GS ;
HAFFAJEE, CI ;
GOLD, RL ;
BISHOP, RL ;
BERKOVITS, BV ;
ALPERT, JS .
CIRCULATION, 1986, 73 (02) :309-315
[17]  
CLELAND JGF, 1987, BRIT HEART J, V57, P436
[18]  
COBB LA, 1975, CIRCULATION S3, V51, P223
[19]   THE USE AND INTERACTION OF PERMANENT PACEMAKERS AND THE AUTOMATIC IMPLANTABLE CARDIOVERTER DEFIBRILLATOR [J].
COHEN, AI ;
WISH, MH ;
FLETCHER, RD ;
MILLER, FC ;
MCCORMICK, D ;
SHUCK, J ;
SHAPIRA, N ;
DELNEGRO, AA .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1988, 11 (06) :704-711
[20]   A HEMODYNAMICALLY RESPONSIVE ANTITACHYCARDIA SYSTEM - DEVELOPMENT AND BASIS FOR DESIGN IN HUMANS [J].
COHEN, TJ ;
LIEM, LB .
CIRCULATION, 1990, 82 (02) :394-406